LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Home・Lista de Ações・Kura Oncology Inc

Kura Oncology Inc

Abrir

SetorSaúde

10.07 0.2

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.86

Máximo

10.18

Indicadores-chave
By Trading Economics
Rendimento	7.7M -73M
Vendas	929K 18M
EPS	-0.828
Margem de lucro	-401.495
Funcionários	260
EBITDA	7.4M -78M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+174.51% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	159M 1B
Abertura anterior	9.87
Fecho anterior	10.07

Sentimento de Notícias

By Acuity

100%

323 / 344 Ranking em Healthcare

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de mai. de 2026, 22:47 UTC

Ganhos

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 de mai. de 2026, 20:45 UTC

Ganhos

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 de mai. de 2026, 23:31 UTC

Conversa de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 de mai. de 2026, 22:37 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 de mai. de 2026, 21:12 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 de mai. de 2026, 21:00 UTC

Ganhos

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 de mai. de 2026, 20:57 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:55 UTC

Ganhos

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

28 de mai. de 2026, 20:48 UTC

Ações em Alta

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 de mai. de 2026, 20:34 UTC

Ganhos

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 de mai. de 2026, 20:31 UTC

Ganhos

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 de mai. de 2026, 20:28 UTC

Ganhos

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 de mai. de 2026, 20:26 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Membership Fees $1.37B

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Net Sales $69.15B

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

174.51% parte superior

Previsão para 12 meses

Média 28.11 USD 174.51%

Máximo 40 USD

Mínimo 15 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

323 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.